|Articles|August 6, 2014
Risk and Innovation in Biopharma: A CEO’s Perspective
Author(s)Guest Blogger
In this Applied Clinical Trials article, Kadmon CEO Dr. Sam Waksal talks about the importance of imagination for innovation, current business risks in biopharma, and applying understanding to the concept of Big Data.
Advertisement
In this Applied Clinical Trials article, Kadmon CEO Dr. Sam Waksal talks about the importance of imagination for innovation, current business risks in biopharma, and applying understanding to the concept of Big Data.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Trump Administration Adds Nine Drugmakers to Most-Favored-Nation Program: Report
2
Eli Lilly to Acquire Merida Biosciences for $2.8 Billion
3
The Future Relationship Between AI and Field Reps
4
BioNTech Terminates Phase II Clinical Trial for Cevumeran
5